<DOC>
	<DOC>NCT01419470</DOC>
	<brief_summary>safety and tolerability, pharmacokinetics/efficacy of an escalating, repeat doses of YHD1044 in premature ejaculation</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<criteria>Patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study History of premature ejaculation in the 6 months before study initiation History of intravaginal ejaculatory latency time (IELT) of &lt; = 2 minutes in at least half of events Premature Ejaculation Diagnostic Tool (PEDT) &gt; =11 6 domains of International Index of Erectile Function(IIEF) &gt;= 21 Patient and partner must agree to attempt sexual intercourse at minimum intervals specified in the protocol Patient's partner must have a negative urine pregnancy test at time of screening Medical history which affects ADME in the past 3 years Clinically significant and active disorder in ophthalmic system, gastrointestine, cardiovascular, respiratory system, endocrine system, autoimmune system or malignant tumor, Subjects with clinically significant observations considered as unsuitable based on medical judgment in the physical examination and clinical laboratory tests or a medical history History of psychological disease Clinically significant allergic disease Hypersensitivity to TCA, SSRIs(Clomipramine, sertraline, fluoxetine, dapoxetine) Taken dapoxetine within 3 months Using other forms of therapy for treatment of PE (behavioral therapy or medications applied to the skin) Taken another investigational drug within 1 month History of drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>